LU91172I2 - Melagatran, les stéréoisomères de celui-ci, et lessels physiologiquement acceptables de celui-ci (m elagatran astrazeneca). - Google Patents

Melagatran, les stéréoisomères de celui-ci, et lessels physiologiquement acceptables de celui-ci (m elagatran astrazeneca).

Info

Publication number
LU91172I2
LU91172I2 LU91172C LU91172C LU91172I2 LU 91172 I2 LU91172 I2 LU 91172I2 LU 91172 C LU91172 C LU 91172C LU 91172 C LU91172 C LU 91172C LU 91172 I2 LU91172 I2 LU 91172I2
Authority
LU
Luxembourg
Prior art keywords
elagatran
melagatran
astrazeneca
stereoisomers
acceptable salts
Prior art date
Application number
LU91172C
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9526273A external-priority patent/GB9526273D0/en
Priority claimed from SE9600556A external-priority patent/SE9600556D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of LU91172I2 publication Critical patent/LU91172I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU91172C 1995-12-21 2005-05-11 Melagatran, les stéréoisomères de celui-ci, et lessels physiologiquement acceptables de celui-ci (m elagatran astrazeneca). LU91172I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9526273A GB9526273D0 (en) 1995-12-21 1995-12-21 New prodrugs
SE9600556A SE9600556D0 (sv) 1996-02-15 1996-02-15 New prodrugs
EP96943446A EP0869966B1 (fr) 1995-12-21 1996-12-17 Promedicaments d'inhibiteurs de thrombine

Publications (1)

Publication Number Publication Date
LU91172I2 true LU91172I2 (fr) 2005-07-11

Family

ID=26308368

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91172C LU91172I2 (fr) 1995-12-21 2005-05-11 Melagatran, les stéréoisomères de celui-ci, et lessels physiologiquement acceptables de celui-ci (m elagatran astrazeneca).

Country Status (30)

Country Link
US (4) US5965692A (fr)
EP (3) EP1533318A1 (fr)
JP (1) JP2000504313A (fr)
KR (1) KR100458545B1 (fr)
AR (1) AR005245A1 (fr)
AT (2) ATE204292T1 (fr)
BR (1) BR9612148A (fr)
CA (1) CA2238737A1 (fr)
DE (3) DE69614579T2 (fr)
DK (2) DK0869966T3 (fr)
EE (1) EE04022B1 (fr)
ES (2) ES2128283T3 (fr)
HK (2) HK1016610A1 (fr)
HU (1) HUP9900115A3 (fr)
IL (1) IL124857A0 (fr)
IS (1) IS1836B (fr)
LU (1) LU91172I2 (fr)
MX (1) MX9804623A (fr)
MY (1) MY121222A (fr)
NL (1) NL300179I2 (fr)
NO (1) NO982809L (fr)
NZ (2) NZ324902A (fr)
PL (1) PL187468B1 (fr)
PT (1) PT995755E (fr)
RU (1) RU2176644C2 (fr)
SI (2) SI0995755T1 (fr)
SK (1) SK285588B6 (fr)
TR (1) TR199801151T2 (fr)
TW (2) TWI238827B (fr)
WO (1) WO1997023499A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
US6417161B1 (en) 1998-04-24 2002-07-09 3-Dimensional Pharmaceuticals, Inc. Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
US6274090B1 (en) * 1998-08-05 2001-08-14 Thermogenesis Corp. Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
WO2000042059A1 (fr) 1999-01-13 2000-07-20 Astrazeneca Ab Nouveaux derives d'amidinobenzylamine et leur utilisation comme inhibiteurs de thrombine
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
TR200102912T2 (tr) 1999-04-09 2002-03-21 Basf Ag. Trombin ihtibit”rlerinin ”n ila‡larì.
WO2000061608A2 (fr) * 1999-04-09 2000-10-19 Basf Aktiengesellschaft Inhibiteurs de faible poids moleculaire des proteases du complement
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
WO2001003685A2 (fr) 1999-07-08 2001-01-18 The University Of North Carolina At Chapel Hill Nouveaux promedicaments pour amidines antimicrobiennes
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101762D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab New use
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
GB0123851D0 (en) * 2001-10-04 2001-11-28 Pankhurst Design & Development Dispersing fragrances
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
SE0103590D0 (sv) 2001-10-26 2001-10-26 Astrazeneca Ab New Combination
SE0200198D0 (sv) 2002-01-23 2002-01-23 Astrazeneca Ab New use
US7838560B2 (en) 2002-03-11 2010-11-23 The Medicines Company (Leipzig) Gmbh Urokinase inhibitors, production and use thereof
MXPA04009831A (es) * 2002-04-10 2004-12-07 Esperion Therapeutics Inc Imitaciones de la coenzima-a de acilo, composiciones de las mismas y metodos de manejo del colesterol y usos relacionados.
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0301879D0 (sv) * 2003-06-25 2003-06-25 Astrazeneca Ab New process
EP2292590A3 (fr) * 2003-07-09 2012-05-02 Paratek Pharmaceuticals, Inc. Promédicaments de composés de tétracycline 9-aminométhylé
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
AR050631A1 (es) * 2004-09-09 2006-11-08 Novartis Ag Combinacion de compuestos organicos
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen
DE102009008256A1 (de) 2009-02-10 2010-08-12 Lts Lohmann Therapie-Systeme Ag Prodrugs vom Typ N-hydroxylierter Amidine, Guanidine und/oder Aminohydrazone zur Applikation über die Haut
DE102014108210A1 (de) * 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP4070658A1 (fr) 2021-04-06 2022-10-12 BIORoxx GmbH Utilisation de composés anticoagulants comme rodenticides

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
US4568636A (en) * 1981-03-25 1986-02-04 Pentapharm Ag Tripeptide derivatives
US4395401A (en) * 1981-09-09 1983-07-26 Smithkline Beckman Corporation Renally active dipeptides
HU192646B (en) * 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
ZA86746B (en) * 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
DE3505555A1 (de) * 1985-02-18 1986-09-11 Behringwerke Ag, 3550 Marburg Neue oligopeptidylargininolderivate und deren homologe, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
DE3606480A1 (de) * 1986-02-28 1987-09-03 Behringwerke Ag Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0362002B1 (fr) * 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. Inhibiteurs de protease HIV
ZA897515B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
US5110812A (en) * 1990-06-04 1992-05-05 Bristol-Myers Squibb Co. Azetidin-2-one derivatives as serine protease inhibitors
US5037819A (en) * 1990-06-04 1991-08-06 Bristol-Myers Squibb Company Azetidin-2-one derivatives as serine protease inhibitors
TW201303B (fr) * 1990-07-05 1993-03-01 Hoffmann La Roche
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
GB9019558D0 (en) * 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
IL99527A (en) * 1990-09-28 1997-08-14 Lilly Co Eli Tripeptide antithrombotic agents
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
EP0511347A1 (fr) * 1990-11-15 1992-11-04 Pentapharm A.G. Derives de la phenylalanine metasubstitues
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
CA2075154A1 (fr) * 1991-08-06 1993-02-07 Neelakantan Balasubramanian Aldehydes peptidiques utilises comme agents antithrombotiques
SE9102462D0 (sv) * 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
NZ245039A (en) * 1991-11-12 1994-12-22 Lilly Co Eli N-phenylalanyl and n-phenylglycyl derivatives of the dipeptide of l-azetidine-2-carboxylic acid and l-arginine aldehyde; anti-blood clotting compositions
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
CA2131367A1 (fr) * 1992-03-04 1993-09-16 Sandor Bajusz Nouveaux derives peptidiques anticoagulants et compositions pharmaceutiques en contenant; procede de fabrication
TW223629B (fr) * 1992-03-06 1994-05-11 Hoffmann La Roche
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
US5583146A (en) * 1992-12-02 1996-12-10 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
DE4321444A1 (de) * 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
EP0648780A1 (fr) * 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Inhibiteurs hétérocycliques de thrombine
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
CA2140598C (fr) * 1994-01-27 2010-03-09 Masahiro Ohshima Derives de la prolineamide
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5561146A (en) * 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
SE504185C2 (sv) * 1994-11-08 1996-12-02 Astra Ab Lagringsstabil vattenlösning för infusion av trombininhibitorer
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
NZ302649A (en) * 1995-02-17 2000-01-28 Basf Ag Dipeptide amidine derivatives, preparation and pharmaceutical compositions thereof
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
AU698911B2 (en) * 1995-04-04 1998-11-12 Merck & Co., Inc. Thrombin inhibitors
US5629324A (en) * 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
TWI238827B (en) 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors

Also Published As

Publication number Publication date
IL124857A0 (en) 1999-01-26
NL300179I2 (nl) 2005-06-01
ES2128283T3 (es) 2005-09-01
AR005245A1 (es) 1999-04-28
HK1016610A1 (en) 1999-11-05
NL300179I1 (nl) 2005-05-02
IS1836B (is) 2002-11-25
AU1217897A (en) 1997-07-17
EP0869966A1 (fr) 1998-10-14
US7354905B2 (en) 2008-04-08
KR19990076624A (ko) 1999-10-15
PT995755E (pt) 2002-02-28
EP1533318A1 (fr) 2005-05-25
US5965692A (en) 1999-10-12
MY121222A (en) 2006-01-28
DE69614579D1 (de) 2001-09-20
IS4756A (is) 1998-05-26
MX9804623A (es) 1998-10-31
CA2238737A1 (fr) 1997-07-03
EP0995755A1 (fr) 2000-04-26
KR100458545B1 (ko) 2005-01-15
EE9800187A (et) 1998-12-15
SI0869966T1 (en) 2005-08-31
EP0869966B1 (fr) 2005-03-16
WO1997023499A1 (fr) 1997-07-03
TW541316B (en) 2003-07-11
DK0995755T3 (da) 2001-11-12
TWI238827B (en) 2005-09-01
EP0995755B1 (fr) 2001-08-16
DK0869966T3 (da) 2005-06-20
HK1026214A1 (en) 2000-12-08
US20020142968A1 (en) 2002-10-03
ATE204292T1 (de) 2001-09-15
PL187468B1 (pl) 2004-07-30
US6262028B1 (en) 2001-07-17
JP2000504313A (ja) 2000-04-11
US20040162410A1 (en) 2004-08-19
DE122004000046I1 (de) 2005-04-21
ES2163916T3 (es) 2002-02-01
EE04022B1 (et) 2003-04-15
NO982809L (no) 1998-08-20
BR9612148A (pt) 1999-07-13
NZ324902A (en) 2000-06-23
DE69634492T2 (de) 2006-04-13
PL327569A1 (en) 1998-12-21
TR199801151T2 (xx) 1998-08-21
DE69614579T2 (de) 2002-06-27
DE69634492D1 (de) 2005-04-21
HUP9900115A3 (en) 1999-11-29
NO982809D0 (no) 1998-06-18
HUP9900115A2 (hu) 1999-05-28
SI0995755T1 (en) 2002-02-28
SK82198A3 (en) 1998-12-02
NZ504245A (en) 2004-11-26
RU2176644C2 (ru) 2001-12-10
SK285588B6 (sk) 2007-04-05
DE122004000046I2 (de) 2011-06-16
ES2128283T1 (es) 1999-05-16
AU706350B2 (en) 1999-06-17
ATE291031T1 (de) 2005-04-15

Similar Documents

Publication Publication Date Title
LU91172I2 (fr) Melagatran, les stéréoisomères de celui-ci, et lessels physiologiquement acceptables de celui-ci (m elagatran astrazeneca).
IS4963A (is) Setnar 6,5-heteró-bísýklískar afleiður
TR199700219A3 (tr) 1,25-Dihidroksi-16, 22, 23-Trisdihidro-kolkalsiferol türevleri.
ZA964116B (en) 2-(2-(hetryloxymethylene) phenyl) crotonates, their preparation and their use.
TR199600579A2 (tr) N-N-Dietil-8,8-Dipropil-2-Azaspiro (4.5) Dekan-2-propanamid dimaleat.
ES1033082Y (es) Cajetilla de tabaco perfeccionada.
AU7098391A (en) New azaspyro(4.5)decane-7,9-dione derivatives
ES1030601Y (es) Radiador-convector, perfeccionado.
ES1029483Y (es) Sembrador perfeccionado.
ES1031073Y (es) Pitillera perfeccionada.
ES1026567Y (es) Protesis peneana, mejorada.
ES1030734Y (es) Tapon-llavero, perfeccionado.
ES1032746Y (es) Futbolin perfeccionado.
ES1032127Y (es) Portajabon perfeccionado.
ES1032350Y (es) Sembradora perfeccionada.
ES1030288Y (es) Papelera perfeccionda.
ES1033065Y (es) Conjunto canula-tapa, perfeccionado.
ES1029716Y (es) Embalaje paletizable o similar, perfeccionado.
ES1029906Y (es) Tendal perfeccionado.
ES1031999Y (es) Caja-expositor perfeccionada.
ES1032389Y (es) Cajon-expositor perfeccionado.
ES1032757Y (es) Cubilete perfeccionado.
ES1032805Y (es) Talocha perfeccionada.
ES1031495Y (es) Palmilla perfeccionada.
ES1030561Y (es) Roldana perfeccionada.